Sun Upbeat On IL-23 Prospects In US, Ilumya Faring ‘Reasonably’
Indian Firm’s China, Japan Plans Gather Pace
Sun expects interleukin-23-targeting drugs to stay a preferred treatment option for psoriasis in the US and saw some sales uptick for its Ilumya in that market in Q2, although it isn’t keen on an auto injector option. Management was also upbeat on prospects in China and Japan.
You may also be interested in...
Sun Pharma says that the first quarter of 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody
Sun’s key specialty asset Ilumya makes progress, albeit slowly, in the US, while the firm sees ‘short window’ to ensure that Absorica LD gains grip in that market ahead of impending arrival of generic.